Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from BioGaia AB ( ($SE:BIOG.B) ) is now available.
BioGaia AB, in collaboration with the University of Gothenburg, has discovered that specific gut bacteria can produce serotonin, a key neurotransmitter. This finding not only enhances understanding of the microbiota-gut-brain axis but also opens potential for developing innovative probiotic products targeting gut and mental health, particularly for conditions like irritable bowel syndrome.
The most recent analyst rating on ($SE:BIOG.B) stock is a Buy with a SEK116.00 price target. To see the full list of analyst forecasts on BioGaia AB stock, see the SE:BIOG.B Stock Forecast page.
More about BioGaia AB
BioGaia is a Swedish probiotic company that has been a leader in microbiome research for over 35 years. The company develops, manufactures, markets, and sells probiotic products focusing on gut, immune, and oral health, distributed in over 100 markets worldwide.
Average Trading Volume: 165,610
Technical Sentiment Signal: Strong Buy
Current Market Cap: SEK10.75B
Find detailed analytics on BIOG.B stock on TipRanks’ Stock Analysis page.